U.K. company touts study of its cancer diagnostic

U.K. company Zilico has published a case study of its diagnostic for high-grade cervical intraepithelial neoplasia, dubbed ZedScan. Use of the technology improved the detection rate of the cancer by 12.4%, the company says. It uses electrical impedance spectroscopy to differentiate between normal, precancerous and cancerous tissues. More

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

To bring its nerve-stimulating wearable to market, Cala Health collected $50 million that it also plans to use to expand its therapeutic pipeline.

The FDA cleared a handful of diagnostics aimed at STIs, including the first to detect chlamydia and gonorrhea outside the genitals.